Rebecca Dent
National Cancer Centre Singapore(SG)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research
Most-Cited Works
- → Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence(2007)5,036 cited
- → Pembrolizumab for Early Triple-Negative Breast Cancer(2020)2,940 cited
- → ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer(2021)1,286 cited
- → Pattern of metastatic spread in triple-negative breast cancer(2008)555 cited
- → Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy(2009)505 cited
- → Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial(2021)479 cited
- → Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design(2009)468 cited
- → Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial(2017)466 cited
- → Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial(2013)433 cited
- → Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study(2020)425 cited